Table 1.
Demographics, cardiovascular risk factors, and disease-related data in RA patients
| RA (n = 1279) | |
|---|---|
| Age, years | 58 ± 13 |
| Female, n (%) | 982 (72) |
| BMI, kg/m2 | 28 ± 5 |
| Abdominal circumference, cm | 94 ± 15 |
| Cardiovascular data | |
| CV risk factors, n (%) | |
| Current smoker | 326 (25) |
| Obesity | 354 (28) |
| Dyslipidemia | 611 (48) |
| Hypertension | 468 (37) |
| Diabetes mellitus | 0 (0) |
| Blood pressure, mmHg | |
| Systolic | 131 ± 17 |
| Diastolic | 78 ± 10 |
| Lipids | |
| Total cholesterol, mmol/l | 5.28 ± 0.96 |
| Triglycerides, mmol/l | 1.27 ± 0.70 |
| HDL cholesterol, mmol/l | 1.58 ± 0.44 |
| LDL cholesterol, mmol/l | 3.10 ± 0.80 |
| Atherogenic index | 3.56 ± 1.06 |
| Statins, n (%) | 303 (24) |
| Aspirin, n (%) | 43 (3) |
| Antihypertensive treatment, n (%) | 335 (26) |
| Disease-related data | |
| Disease duration, years | 5 (2–12) |
| CRP at time of study, mg/l | 2.7 (0.9–6.7) |
| ESR at time of study, mm/1° h | 12 (5–23) |
| Rheumatoid factor, n (%) | 753 (59) |
| ACPA, n (%) | 682 (53) |
| DAS28-ESR | 3.09 ± 1.49 |
| DAS28-PCR | 2.99 ± 1.28 |
| SDAI | 10 (5–18) |
| CDAI | 9 (4–16) |
| HAQ | 0.750 (0.250–1.250) |
| RAPID | 3.15 ± 2.03 |
| Current drugs, n (%) | |
| Prednisone | 636 (50) |
| Prednisone doses, mg/day | 5 (4–6) |
| NSAIDs | 498 (39) |
| DMARDs | 983 (77) |
| Methotrexate | 730 (57) |
| Leflunomide | 141 (11) |
| Hydroxychloroquine | 282 (22) |
| Sulphasalazine | 44 (3) |
| Anti-TNF therapy | 166 (13) |
| Adalimumab | 56 (4) |
| Infliximab | 18 (1) |
| Etanercept | 66 (5) |
| Golimumab | 5 (0) |
| Tocilizumab | 65 (5) |
| Rituximab | 21 (2) |
| Abatacept | 22 (2) |
| Baricitinib | 12 (1) |
| Tofacitinib | 14 (1) |
| Historical disease-related data | |
| History of extraarticular manifestations, n (%) | 232 (18) |
| Erosions, n (%) | 453 (35) |
| CRP at time of disease diagnosis, mg/l | 7.0 (2.0–20.0) |
| CRP > 3 at time of diagnosis, n (%) | 685 (54) |
| ESR at the time of disease diagnosis, mm/1° h | 21 (11.38) |
| Subclinical atherosclerosis | |
| Carotid IMT, μm | 690 ± 140 |
| Carotid plaques, n (%) | 678 (53) |
Data represent means ± SD or median (IQR) when data were not normally distributed
CV cardiovascular, LDL low-density lipoprotein, HDL high-density lipoprotein, CRP C-reactive protein, NSAID nonsteroidal anti-inflammatory drugs, DMARD disease-modifying antirheumatic drug, TNF tumor necrosis factor, Obesity, ESR erythrocyte sedimentation rate, BMI body mass index, DAS28 Disease Activity Score in 28 joints, ACPA anti-citrullinated protein antibodies, RAPID routine assessment of patient index, CDAI Clinical Disease Activity Index, SDAI Simple Disease Activity Index, HAQ Health Assessment Questionnaire